Dr. Adrian Schomburg
Dr. Adrian Schomburg is the CEO and co-founder of Eisbach Bio, a Munich based oncology drug discovery company built on strong nucleosome based assays and disease biology. Adrian is also the founder of Octamer – which focuses on the development and production of high-quality nucleosomes for industrial use. This is based on Adrian’s 10 year’s+ experience in histone and nucleosome production which he initiated during his tenure at the NIH, Bethesda and the Max Planck Institute in Göttingen.
In addition to being an epigenetics entrepreneur, Adrian manages a range of projects that delivered preclinical and development candidates in oncology and neuroscience.